Since we observed
robust inhibition of NFκB in the presence of RIPK2 inhibitor 1 and a
> 70 %
recovery of animals from DSS - induced inflammation injury (Figs. 4 and 6B), we proceeded to explore the ability to resolve lung inflammation using the ovalbumin challenge model (Kumar et al., 2008).
However, the group receiving the PA - RGDS - encapsulated hPSC - ECs showed better perfusion
recovery, more
robust and longer cell survival (
> 10 months), and higher and prolonged angiogenic and vascular incorporation capabilities than the bare hPSC - EC - injected group.